UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **September 23, 2021**

PTC THERAPEUTICS, INC.

(Exact Name of Company as Specified in Charter)

Delaware	**001-35969**	**04-3416587**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

100 Corporate Court **South Plainfield, NJ** (Address of Principal Executive Offices)	**07080** (Zip Code)

Registrant's telephone number, including area code: **(908) 222-7000**

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, $0.001 par value per share	PTCT	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

As previously announced, PTC Therapeutics, Inc. (the "Company") will host a conference call on September 23, 2021 at 8:00 a.m. eastern time. During this conference call, the Company expects to discuss the results from the PTC518 Phase 1 healthy volunteer study and provide an update on the PTC518 Phase 2 study, to be conducted in Huntington's disease patients. A copy of the slide deck that will be presented during the conference call is attached as Exhibit 99.1.

The information in this Report (including Item 7.01 and Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Corporate Presentation – PTC518 Huntington's Disease Program Update
104	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

PTC Therapeutics, Inc.

Date: September 23, 2021

By: /s/ Emily Hill
Name: Emily Hill
Title: Chief Financial Officer

Exhibit 99.1


PTC518 Huntington
Disease Program
Update
September 23, 2021

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statem contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data and c matters; PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Othe forward-looking statements may be identified by the words "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "ta "potential," "will," "would," "could," "should," "continue," and similar expressions.

PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it m as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; the enrollment, con and results of PTC518 clinical studies for HD; significant business effects, including the effects of industry, market, economic, political or regu conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's product product candidates; PTC's scientific approach and general development progress; and the factors discussed in the "Risk Factors" section of F most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SE are urged to carefully consider all such factors.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful.

The forward-looking statements contained herein represent PTC's views only as of the date of this presentation and PTC does not undertake to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this presentation except as required by law.

Small Molecule Splicing Modulation Platform

Identify Splice Site targets → **Identification of splicing compound** → **Preclinical Pipeline** → **Clinical Target Pipeline** → **Approved Drug**



5' Splice Site



3' Splice Site



HTrnaSeq

HTSpliceoseq

Nanostring Plex Screen

Spinal Muscular Atrophy - *SMN*

Evrysdi® risdiplam

Huntington's Disease
HTT

Familial Dysautonomia
IKBKAP

MAPT-Tauopathies
ATXN3-SCA3
Undisclosed target 1
Undisclosed target 2
Undisclosed target 3
Undisclosed target 4
Undisclosed target 5

Evrysdi™ (risdiplam) Roadmap to Success



PTC518 Huntington's Disease Program Update Agenda



Huntington's Disease Is a Debilitating Neurodegenerative Disorder with No Available Disease Modifying Treatments

Huntington's Disease

- Caused by a monogenic defect; autosomal dominant inheritance
- Leads to movement, psychiatric and cognitive disorders
- 135,000 patients worldwide

Current Treatments

- No approved disease modifying therapies

HD Is a Monogenic Gain of Function Disorder and Lowering HTT Targets The Root Cause of Pathogenesis



Toxic gain of function mutation
Expansion of CAG repeat in huntingtin (HTT) gene

Huntington's disease
Whole brain atrophy
HTT protein aggregates

Therapeutic approach:
Make less HTT

 Modified from Tabrizi,S. *Cell*.2019.

HD Is a Monogenic Gain of Function Disorder and Lowering HTT Targets The Root Cause of Pathogenesis

Toxic gain of function mutation
Expansion of CAG repeat in huntingtin (HTT) gene

Huntington's disease
Whole brain atrophy
HTT protein aggregates

Therapeutic approach:
Make less HTT

Multiple models demonstrate partial reduction of wild type HTT is well tolerated

HTT reduction correlates with clinical benefit

 Modified from Tabrizi,S. *Cell*.2019.

Identification of a Novel Splicing Mechanism that Leads t Degradation of Mutant HTT mRNA

No compound

Pseudoexon is not spliced in;
full length HTT protein is produced

With PTC518

Pseudoexon is spliced in;
Nonsense mutation leads
to mRNA degradation



Nonsense-mediated *HTT* mRNA decay

Characteristics of PTC518 Were Demonstrated in Preclinical Studies

- Orally bioavailable and penetrates blood brain barrier
- Reduces HTT mRNA and protein in the CNS and periphery
- Reversible and titratable
- Uniform lowering in key regions of the brain
- Not effluxed
- Highly selective




PTC518 Phase
Healthy
Volunteer Study

The PTC518 Phase 1 Trial Was a 4-Part Study



Proof of Mechanism of PTC518 Was Confirmed By Dose-Dependent *HTT* mRNA Splicing in Healthy Volunteers

SAD Study



- Whole blood *HTT* splicing in humans
  - Doses evaluated = 5mg, 15mg, 45 mg, 90 mg, and 135 mg
  - Time – one day; single dose; splicing evaluated 24h post dose

MAD Study



- Whole blood *HTT* splicing in humans
  - Doses evaluated = 15 mg and 30 mg
  - Time – Day 14; multiple doses; splicing evaluated 6h post dose on day 14

Phase 1 SAD & MAD Interim Results Showed That PTC51 Reduced HTT mRNA in a Dose-Dependent Manner



Well tolerated

Predictable pharmacology

Dose-dependent splicing of HTT mRNA

MAD showed long drug half-life with maintenance of splicing up to 72 hours following last dose

Decay Rates Can Be Modeled To Predict Drug-Dependent Decrease in mRNA and Protein Concentration Over Time



PTC518 Is Predicted to Achieve Equivalent HTT mRNA and Protein Reduction at Steady-State

HTT mRNA abundance
Steady state lowering should reach within 1 week



HTT protein abundance
Steady state lowering should take ≥6 weeks



 Data on file

PTC518 Is Predicted to Achieve Equivalent HTT mRNA and Protein Reduction at Steady-State





 Data on file

The PTC518 Phase 1 Trial Was a 4-Part Study



PTC518 Crosses the Blood Brain Barrier in Non-Human Primates and Humans





The PTC518 Phase 1 Trial Was a 4-Part Study



The PTC518 Phase 1 Trial Was a 4-Part Study



Phase 1 Results Showed That PTC518 Reduced HTT mRNA and Protein in a Dose-Dependent Manner and Passed the Blood Brain Barrier



Well tolerated

Predictable pharmacology



Dose-dependent reduction of HTT mRNA and Protein



PTC518 levels in the CSF are equal to or greater than levels observed in blood

Results Confirm Exposure of PTC518 Can Lead to Clinically Meaningful HTT Reduction mRNA and Protein




PTC518
Phase 2 Study
Design

Phase 2 study objectives

Strategies For Potential FDA Approval



PTC518 Phase 2 Study – PIVOT HD Planned Study Design



- Double blind, multiple dose, 12-week placebo-controlled study with a long-term open label extension
- Global clinical trial
- N~100-150 patients
- Trial to initiate by YE2021

PIVOT HD Endpoint Strategy

Primary endpoints

- Safety and tolerability of PTC518 in Huntington's disease patients
- Percent reduction in HTT mRNA and protein in blood

Biomarker endpoints

- Percent reduction in HTT protein in CSF
- Changes in neurofilament light chain (NfL) in plasma and CSF
- Change in caudate, putamenal, ventricular volume on volumetric MRI imaging

Clinical endpoints

- Changes in clinical scales of motor and cognitive function

Identifying Optimal Clinical Trial Population

Finding the Goldilocks Population



Optimal Endpoints Vary by Disease Stage



 Schematic adapted from Natural History Analyses

PIVOT HD Inclusion Criteria

- Age 25 years and older
- Ambulatory
- CAG repeat 42-50 inclusive
- Specific clinical and radiographic parameters
  - Brain volumetric MRI values
  - Total motor score (TMS)
  - Cognitive score
  - Prognostic index of Huntington's disease (PIN_{HD})

Summary

Phase 1 completed with achievement of all study objectives including protein reduction and projected CSF exposure

Phase 2 trial to be initiated by YE 2021

- Multiple dose placebo-controlled trial of PTC518 in HD patients
- Study designed to capture biomarker effects that could potentially support accelerated approval
- Inclusion criteria optimized based on extensive natural history data analyses


Questions